Literature DB >> 1871786

Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus.

B R Bhavnani1, C A Woolever.   

Abstract

The present investigation was undertaken to compare the binding affinities (Ka) of the ring B unsaturated equine estrogens (equilin [Eq], equilenin [Eqn], 17 beta-dihydroequilin [17 beta-Eq], 17 beta-dihydroequilenin [17 beta-Eqn], 17 alpha-dihydroequilin [17 alpha-Eq], and17 alpha-dihydroequilenin [17 alpha-Eqn]) and the classic estrogens (estrone [E1], 17 beta-estradiol [17 beta-E2], and 17 alpha-estradiol [17 alpha-E2]) for estrogen receptors in human endometrium and rat uterus. In both species, the ring B unsaturated estrogens bind with cytosol and nuclear receptors with high affinity (Ka x 10(9) M-1). The relative binding affinities of these estrogens were measured by determining the amount of unlabeled estrogen required to reduce by 50% the specific binding of [3H]17 beta-Eq to endometrial cytosol receptors. The order of activity found was 17 beta-Eq greater than 17 beta-E2 greater than 17 beta-Eqn greater than E1 greater than Eq greater than 17 alpha-Eq greater than 17 alpha-E2 greater than 17 alpha-Eqn greater than Eqn. Essentially the same order of activity was observed when the apparent affinity constants of these estrogens for human and rat cytosol and nuclear receptors were determined by a competitive (inhibition) binding assay. Sucrose density gradient analysis indicated that these estrogens form protein complexes with cytosol and nuclear preparation that sediment at approximately 8S and 4S, respectively. The affinity constants for 17 beta-Eq were approximately two- to six-fold higher than E2 in both species. In a rat uterotropic assay, all nine estrogens were uterotropic. These data indicate that all ring B unsaturated estrogens present in conjugated equine estrogen preparations are biologically active and they express their biologic effects in the human endometrium by mechanisms similar to those described for the classic estrogens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871786     DOI: 10.1016/0039-128x(91)90083-8

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  5 in total

1.  Unexpected hormonal activity of a catechol equine estrogen metabolite reveals reversible glutathione conjugation.

Authors:  Kuan-Wei Peng; Minsun Chang; Yue-Ting Wang; Zhican Wang; Zhihui Qin; Judy L Bolton; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2010-08-16       Impact factor: 3.739

2.  During development, 17alpha-estradiol is a potent estrogen and carcinogen.

Authors:  R A Hajek; A D Robertson; D A Johnston; N T Van; R K Tcholakian; L A Wagner; C J Conti; M L Meistrich; N Contreras; C L Edwards; L A Jones
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

3.  Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease.

Authors:  Liqin Zhao; Roberta Diaz Brinton
Journal:  BMC Neurosci       Date:  2006-03-13       Impact factor: 3.288

4.  Differential effects of oral and transdermal menopausal hormone therapy on prostacyclin and thromboxane in platelets.

Authors:  Limor Raz; Larry W Hunter; Muthuvel Jayachandran; John A Heit; Virginia M Miller
Journal:  Physiol Rep       Date:  2014-03-27

5.  Potential role of the interaction between equine estrogens, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the prevention of coronary heart and neurodegenerative diseases in postmenopausal women.

Authors:  Joel Perrella; Mauricio Berco; Anthony Cecutti; Alan Gerulath; Bhagu R Bhavnani
Journal:  Lipids Health Dis       Date:  2003-06-20       Impact factor: 3.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.